Effects of simvastatin 40 mg daily on muscle and liver adverse effects in a 5-year randomized placebo-controlled trial in 20,536 high-risk people
Open accessThe DOI matches its Crossref record; 29 of the 30 references it cites were found in a registry or an index.
Abstract
Background: Simvastatin reduces cardiovascular mortality and morbidity but, as with other HMG-CoA reductase inhibitors, can cause significant muscle toxicity and has been associated with elevations of liver transaminases. Methods: Muscle and liver adverse effects of simvastatin 40 mg daily were evaluated in a randomized placebo-controlled trial involving 20,536 UK patients with vascular disease or diabetes (in which a substantial reduction of cardiovascular mortality and morbidity has previously been demonstrated). Results: The excess incidence of myopathy in the simvastatin group was < 0.1% over the 5 years of the trial, and there were no significant differences between the treatment groups in the incidence of serious hepatobiliary disease. Conclusion: Among the many different types of high-risk patient studied (including women, older individuals and those with low cholesterol levels), there was a very low incidence (< 0.1%) of myopathy during 5 years treatment with simvastatin 40 mg daily. The risk of hepatitis, if any, was undetectable even in this very large long-term trial. Routine monitoring of liver function tests during treatment with simvastatin 40 mg is not useful. Trial Registration: ISRCTN48489393
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Muscle complaints in other clinical trials have been similar in statin-treated and placebo subjects.4,20,23,24”
In the citing paper
“In the vast majority of cases, SAMS are not accompanied by marked CK elevation.24,29”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
OLSSON, A. G., McMurray, J. J. V., Thorgeirsson, G., Spaulding, C. M., Slattery, J., Pyörälà, K., Færgeman, O., Wright, R. S., Berg, K. M., Wilhelmsen, L., et al. (1994) · The Lancet · Cited by 8,467
SCANDINAVIANSIMVASTATINSURVIVAL (1994) · The Lancet · doi:10.1016/s0140-6736(94)90566-5 · Cited by 3,645
SLCO1B1 Variants and Statin-Induced Myopathy — A Genomewide Study
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801936 · Cited by 2,043 · cited 2×
“This difference is not statistically significant, but – given that myopathy is a well-established adverse effect of simvastatin (and of other statins, particularly at higher doses [15,22]) and the cases in the placebo group had predisposing factors – it is likely that some of this excess was caused by simvastatin.”
BackgroundThompson, P. D., Clarkson, P., & Karas, R. H. (2003) · JAMA · doi:10.1001/jama.289.13.1681 · Cited by 1,463
Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors
Tobert, J. A. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1112 · Cited by 875 · cited 2×
“This difference is not statistically significant, but – given that myopathy is a well-established adverse effect of simvastatin (and of other statins, particularly at higher doses [15,22]) and the cases in the placebo group had predisposing factors – it is likely that some of this excess was caused by simvastatin.”
BackgroundStatin Safety: A Systematic Review
Law, M., & Rudnicka, A. R. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.010 · Cited by 808 · cited 1×
“Few drugs have toxic effects on skeletal muscle, but all statins occasionally cause myopathy [11-13].”
BackgroundRisk for Myopathy With Statin Therapy in High-Risk Patients
Ballantyne, C. M., Corsini, A., Davidson, M. H., Holdaas, H., Jacobson, T. A., Leitersdorf, E., März, W., Reckless, J. P. D., & Stein, E. A. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.5.553 · Cited by 453
Efficacy and long-term adverse effect pattern of lovastatin
Tobert, J. A. (1988) · The American Journal of Cardiology · doi:10.1016/0002-9149(88)90004-5 · Cited by 335 · cited 3×
“In this context, myopathy is generally defined as unexplained muscle pain or weakness accompanied by a creatine kinase (CK) level >10 times the upper limit of normal (ULN)[11,14].”
BackgroundPedersen, T. R. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.156.18.2085 · Cited by 286
Statin Safety: An Overview and Assessment of the Data—2005
Bays, H. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.006 · Cited by 264
Serum Transaminase Elevations as Indicators of Hepatic Injury Following the Administration of Drugs
Amacher, D. E. (1998) · Regulatory Toxicology and Pharmacology · doi:10.1006/rtph.1998.1201 · Cited by 247 · cited 1×
“By contrast, drugs that are hepatotoxic typically produce marked transaminase elevations at a rate that is much higher than the incidence of clinical hepatitis[24].”
BackgroundTolman, K. G. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02355-x · Cited by 214
Howard, W. J. (2008) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)79115-7 · Cited by 209
Drug-Induced Hepatotoxicity: 2005
Maddrey, W. C. (2005) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000155548.91524.6e · Cited by 201 · cited 3×
“Liver function monitoring during HPS was intensive, with ALT (which is considered to be most sensitive to statin-induced changes[20]) measured at every visit, so it cannot be proved that such monitoring did not prevent some patients from proceeding to hepatitis.”
BackgroundInfluentialPedersen, T. R., & Tobert, J. A. (2004) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.5.12.2583 · Cited by 140 · cited 1×
“Background The HMG-CoA reductase inhibitor simvastatin is widely used to lower LDL cholesterol and reduce cardiovascular risk[1].”
BackgroundSEARCH Study Collaborative Group (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.06.034 · Cited by 123 · cited 1×
“It remains uncertain whether, these conclusions can be extrapolated to simvastatin 80 mg daily (the maximal recommended dose of this drug), and this is now being assessed as part of a large-scale direct randomized comparison of 80 mg versus 20 mg simvastatin daily[22,25].”
BackgroundLi, T. C., Versland, M. R., & Wu, G. Y. (1998) · Diseases of the Liver and Bile Ducts · doi:10.1007/978-1-4612-1808-1_13 · Cited by 119
Smith, C. C., Bernstein, L. I., Davis, R. B., Rind, D. M., & Shmerling, R. H. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.6.688 · Cited by 110 · cited 1×
“Routine monitoring of liver function has been recommended in the prescribing information for all statins, but its usefulness has subsequently been questioned[16,18].”
Background(2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.08.052 · Cited by 110
Heart Protection Study Collaborative Group (2005) · BMC Medicine · doi:10.1186/1741-7015-3-6 · Cited by 101
Estimating the effect of the run‐in on the power of the physicians' health study
Lang, J. M., Buring, J. E., Rosner, B., Cook, N., & Hennekens, C. H. (1991) · Statistics in Medicine · doi:10.1002/sim.4780101010 · Cited by 99 · cited 1×
“Prior to randomization, many potential drop-outs were excluded during the run-in period or at the randomization visit in order to improve the statistical sensitivity of HPS to assess the efficacy of prolonged simvastatin [21].”
BackgroundIssues in Statin-Associated Myopathy—Reply
Luh, J. Y., & Karnath, B. M. (2003) · JAMA · doi:10.1001/jama.290.7.888-c · Cited by 13
Cited by
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Interpretation of the evidence for the efficacy and safety of statin therapy
Collins, R., Reith, C., Emberson, J., Armitage, J., Baigent, C., Blackwell, L., Blumenthal, R., Danesh, J., Smith, G. D., DeMets, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31357-5 · Cited by 1,857
Stroes, E. S., Thompson, P. D., Corsini, A., Vladutiu, G. D., Raal, F. J., Ray, K. K., Roden, M., Stein, E., Tokgözoğlu, L., Nordestgaard, B. G., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv043 · Cited by 1,443
Newman, C. B., Preiss, D., Tobert, J. A., Jacobson, T. A., Page, R. L., Goldstein, L. B., Chin, C., Tannock, L. R., Miller, M., Raghuveer, G., et al. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atv.0000000000000073 · Cited by 738
“In HPS, in which >20 000 patients were randomized to simvastatin 40 mg or placebo for 5 years, there were 6 and 9 cases, respectively, of clinical hepatitis.(38) In a meta-analysis”
A systematic review of statin-induced muscle problems in clinical trials
Ganga, H. V., Slim, H. B., & Thompson, P. D. (2014) · American Heart Journal · doi:10.1016/j.ahj.2014.03.019 · Cited by 253
Metadata
- Authors
- MRC/BHF Heart Protection Study Collaborative Group
- Affiliations
- University of Oxford (GB)
- Corresponding author
- MRC/BHF Heart Protection Study Collaborative Group
- Venue
- BMC Clinical Pharmacology
- Published
- 2009-03-31
- Volume
- 9
- Issue
- 1
- Pages
- 6-6
- ISSN
- 1472-6904 (ISSN-L)
- PMC
- PMC2676245
- OpenAlex
- W1628749699
- Cited by
- 70
- References
- 30
- Citations by year
- 2025: 2 · 2024: 1 · 2023: 2 · 2022: 5 · 2021: 4 · 2020: 6 · 2019: 2 · 2018: 2 · 2017: 1 · 2016: 3 · 2015: 7 · 2014: 13 · 2013: 3 · 2012: 7
- FWCI
- 6.42
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- BMC Clinical Pharmacology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- British Heart Foundation
- Medical Research Council (MC_EX_G0801669)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Drug-Induced Hepatotoxicity and Protection
- Keywords
- simvastatin, myopathy, hepatotoxicity, liver transaminases, statins, statin adverse effects, long-term drug safety, vascular disease, diabetes mellitus, liver function monitoring, high-risk patients
- MeSH terms
- Aged, Anticholesteremic Agents, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Liver, Middle Aged, Muscles, Muscular Diseases, Patient Compliance, Placebos, Risk Factors, Incidence, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Simvastatin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.